Roche's Challenging Biomarker Strategy

Large pharma companies are increasingly interested in using biomarkers to shorten R&D timelines and reduce the risks of developing new drugs. Roche says its recently formalized biomarker program benefits from the firm's unique expertise in diagnostics. But like its competitors embarked on siimilar efforts, Roche won't know the value of this complex undertaking for years.